Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.77 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.77 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.77 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.77 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.77 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.74 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.70 |
| ▸ | PPARG | P37231 | 7/20 | 0.70 |
| ▸ | PPARD | Q03181 | 7/20 | 0.70 |
| ▸ | PPARA | Q07869 | 7/20 | 0.70 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.70 |
| ▸ | TSHR | P16473 | 4/20 | 0.70 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.70 |
| ▸ | FABP4 | P15090 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | TLR2 | O60603 | 2/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butyric Acid SCHEMBL4783360 | 1.00 | FFAR3 (0.77) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL2676630 | 0.97 | FFAR3 (0.72) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Heptane SCHEMBL8097495 | 0.97 | GPR84 (0.75) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL6418455 | 0.97 | FFAR3 (0.81) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL7471228 | 0.97 | FFAR3 (0.81) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL23014527 | 0.97 | FFAR3 (0.81) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL59956 | 0.97 | FFAR3 (0.81) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL4229756 | 0.97 | FFAR3 (0.81) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL7462002 | 0.97 | FFAR3 (0.81) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL2807771 | 0.97 | FFAR3 (0.81) | FFAR3HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070224213-A1 | Pharmaceutical Composition Comprising an Extract or Compounds Isolated from Elfvingia Applanata for the Prevention and the Treatment of Diabetes and Diabetic Complications | SON, DAL-HOON (CA) | 2007-09-27 | — | — | US | claimed |
| US-9861941-B2 | Modified sulfonated block copolymers and the preparation thereof | KRATON POLYMERS U.S. LLC (US) | 2018-01-09 | — | — | US | disclosed |
| EP-2731998-B1 | MODIFIED SULFONATED BLOCK COPOLYMERS AND THE PREPARATION THEREOF | KRATON POLYMERS US LLC (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-2731998-A1 | MODIFIED SULFONATED BLOCK COPOLYMERS AND THE PREPARATION THEREOF | Kraton Polymers US LLC (US) | 2014-05-21 | — | — | EP | disclosed |
| WO-2013025271-A1 | MODIFIED SULFONATED BLOCK COPOLYMERS AND THE PREPARATION THEREOF | KRATON POLYMERS U.S. LLC (US) | 2013-02-21 | — | — | WO | disclosed |
| US-20130015071-A1 | MODIFIED SULFONATED BLOCK COPOLYMERS AND THE PREPARATION THEREOF | KRATON POLYMERS U.S. LLC (US) | 2013-01-17 | — | — | US | disclosed |
| EP-2539317-A2 | DIHYDROLIPOIC ACID DERIVATIVES COMPRISING NITRIC OXIDE AND THERAPEUTIC USES THEREOF | Invasc Therapeutics, Inc. (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120041025-A1 | Dihydrolipoic Acid Derivatives Comprising Nitric Oxide and Therapeutic Uses Thereof | CARMEL BIOSCIENCES, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20110257130-A1 | Compositions and Methods for Treatment of Renin-Angiotensin Aldosterone System (RAAS)- Related Disorders | CARMEL BIOSCIENCES, INC. | 2011-10-20 | — | — | US | disclosed |
| EP-2358707-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENIN-ANGIOTENSIN ALDOSTERONE SYSTEM (RAAS)-RELATED DISORDERS | Invasc Therapeutic, Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| US-6362218-B1 | Brefeldin A derivatives | PURDUE RESEARCH FOUNDATION | 2002-03-26 | — | — | US | disclosed |
| US-20020032336-A1 | Process for preparing 1,5-diaryl-3-substituted pyrazoles | ABDEL-MAGID AHMED F (US) | 2002-03-14 | — | — | US | disclosed |
| EP-1144382-A2 | PROCESS FOR PREPARING 1,5-DIARYL-3-SUBSTITUTED PYRAZOLES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001009102-A2 | PROCESS FOR PREPARING 1,5-DIARYL-3-SUBSTITUTED PYRAZOLES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| US-4942226-A | ANTITUMOR AGENTS, RADIATION SENSITIZERS | MERCK & CO., INC. (US) | 1990-07-17 | — | — | US | disclosed |
| US-4935503-A | One step; using peroxydisulfate, ferrous, azide, and chloride salt | BIOMIRA, INC. (CA) | 1990-06-19 | — | — | US | disclosed |
| EP-0340780-A2 | Azidochlorination and diazidization of glycals | BIOMIRA, INC. (CA) | 1989-11-08 | — | — | EP | disclosed |
| US-4847294-A | Derivatives of 2-(substituted sulfamyl)-6-nitrobenzoic acids, useful as adjuncts to radiation therapy | MERCK & CO., INC. (US) | 1989-07-11 | — | — | US | disclosed |
| EP-0265806-A1 | 2-(Substituted sulfamyl)-6-nitrobenzoic acids, amides and esters thereof useful as adjuncts to radiation therapy | MERCK & CO. INC. (US) | 1988-05-04 | — | — | EP | disclosed |
| US-4694020-A | Derivatives of 2-(substituted sulfamyl)-6-nitrobenzoic acids and pharmaceutical compositions | MERCK & CO., INC. (US) | 1987-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032336-A1 | Process for preparing 1,5-diaryl-3-substituted pyrazoles | ADH5, ADH1C, ADH1A | FFAR3 1088/4885HDAC3 789/4885HDAC1 768/4885 |
| US-20120041025-A1 | Dihydrolipoic Acid Derivatives Comprising Nitric Oxide and Therapeutic Uses Thereof | DLD, LDLR, ALOX15 | FFAR3 323/4885HDAC3 2132/4885HDAC1 2149/4885 |
| US-20070224213-A1 | Pharmaceutical Composition Comprising an Extract or Compounds Isolated from Elfvingia Applanata for the Prevention and the Treatment of Diabetes and Diabetic Complications | DPP7, DPP4, ELF3 | FFAR3 489/4885HDAC3 1288/4885HDAC1 715/4885 |
| US-20110257130-A1 | Compositions and Methods for Treatment of Renin-Angiotensin Aldosterone System (RAAS)- Related Disorders | REN, ACE, AGT | FFAR3 3619/4885HDAC3 3633/4885HDAC1 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.